“The emergence of biologic materials is one of the recent developments of spine fusion surgery. Earlier, autografts were considered as the ideal primary bone graft. However, allograft evolved as a better treatment option, owing to various associated complications such as pain, infection, and weakened bone. Thus, the use of biologics in spine surgeries is expected to witness higher demand in the future because of the constant development of new products.”
The report provides in-depth analyses of the key winning strategies, drivers & opportunities, market size & estimations, key market segments, and competitive landscape. According to the report, the global spine biologics market accounted for $1.64 billion in 2015 and is expected to garner $2.21 billion by 2022, registering a CAGR of 4.3% from 2014 to 2022.
Rise in geriatric population, advantages of biologic materials, and shift toward minimally invasive spine procedures are the major drivers of the global spine biologics market. However, high cost and ethical concerns related to grafting hamper market growth. On the contrary, untapped potential in the emerging economies is expected to create lucrative opportunities in the near future.
Get Sample Report: https://www.alliedmarketresearch.com/request-sample/1955
Global spine biologics market is divided into product, surgery, and geography. On the basis of product, the market is segmented into spinal allografts, bone graft substitutes, and cell-based matrix. The demineralized bone matrix segment is projected to register CAGR of 3.4%, owing to its ability to stimulate bone formation. However, the synthetic bone grafts segment reaped more than half of the global bone graft substitutes market in 2015. Based on surgery, the market is bifurcated into open spine surgery and minimally invasive spine surgery.
On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and Latin America, Middle East and Africa (LAMEA). The North America region held the largest market share in 2015, contributing about two-thirds of the market share. Moreover, France and Germany combined accounted for more than one-third of the total share of European spire biologics market in 2015. However, the Asia-Pacific region is expected to manifest the fastest CAGR of 5.3% during the forecast period, owing to improved healthcare infrastructure and increase in expenditure in the developing countries.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1955
The report includes an analysis of the major market players including Alphatec Holdings, Inc., Exactech, Inc., Medtronic plc, Orthofix International N.V., SeaSpine, Depuy Synthes (Johnson & Johnson), Globus Medical, Inc., NuVasive, Inc., RTI Surgical, Inc., and Zimmer Biomet Holdings, Inc. They have adopted various strategies such as mergers & acquisitions, collaborations, partnerships, and others to gain a strong position in the industry.
Key Findings of the Spine Biologics Market:
- The demineralized bone matrix segment is expected to grow at a CAGR of 3.4%, owing to its ability to stimulate bone formation.
- Synthetic bone grafts segment accounted for more than half of the global bone graft substitutes market in 2015.
- North America contributed two-thirds share of the global spine biologics market in 2015.
- France and Germany jointly accounted for more than one-third share of the European spine biologics market in 2015.
- Japan is the major shareholder in the Asia-Pacific spine biologics market, accounting for more than one-third share in 2015.
Scope of The Report:
|Market size available for years||2015-2022|
|Base year considered||2015|
|Forecast units||Value (USD)|
|Segments covered||Product, and Surgery|
|Geographies covered||North America, Europe, Asia-Pacific, LAMEA|
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
Follow Us on Twitter: https://twitter.com/marketresearcht